未经证实:干燥病和瘙痒是透析和糖尿病患者中常见的慢性皮肤病,经常被诊断不足或被忽视。这会影响这些患者的生活质量。本研究旨在评估特定皮肤化妆品在治疗与透析和糖尿病相关的皮肤干燥和瘙痒中的疗效和安全性。
未经评估:29名透析患者(平均年龄62岁)和40名糖尿病患者(平均年龄57岁,88%的2型)被纳入两个不同的单中心开放标签非对照临床试验。所有患者根据缩放粗糙度红度和裂纹(SRRC)量表表现为皮肤干燥,瘙痒和/或失眠。他们使用了真皮化妆品Medi-SecureAtodermXereane(NAOS,生物实验室)一天一次或两次。临床疗效(SRRC,瘙痒,和失眠),与皮肤相关的生活质量(皮肤病生活质量指数,DLQI),并在纳入访视时和产品应用28天后评估主观疗效,以及安全。
未经批准:申请28天后,该产品显着降低了SRRC全球评分83%(0.9±0.8vs5.1±1.2)和66%(1.4±1.2vs4.2±0.5),瘙痒强度为76%(1.1±1.3vs4.6±2.1)和78%(0.9±1.7vs4.2±2.6),透析和糖尿病患者的失眠强度分别为61%(0.9±1.3vs2.4±2.3)和82%(0.9±1.7vs4.8±2.7),分别。此外,在D28时,该产品的应用使透析患者的皮肤相关生活质量改善了50%(5.4vs2.7;p<0.0001),糖尿病患者的皮肤相关生活质量改善了71%(6.6vs1.9;p<0.0001)。此外,该产品因其舒缓而受到所有患者的高度赞赏,安慰,修复,滋养,和补水效果,整个小组都能很好地耐受。
未经授权:这种特殊的皮肤化妆品可显著降低皮肤干燥,瘙痒,透析和糖尿病患者的失眠,从而大大提高了他们与皮肤相关的生活质量。通过管理和避免与他们的疾病或治疗相关的麻烦症状,这种生态生物学皮肤化妆品可以预防严重的并发症,这些并发症对他们的日常生活构成了沉重负担。
UNASSIGNED: Xerosis and pruritus are common chronic dermatological disorders among dialysis and diabetic patients that are frequently underdiagnosed or neglected, which can impact the quality of life of these patients. This study aimed to evaluate the efficacy and safety of a specific dermo-cosmetic product in the treatment of dry skin and pruritus associated with dialysis and diabetes.
UNASSIGNED: Twenty-nine dialysis patients (mean age 62 years) and 40 diabetic patients (mean age 57 years, 88% type 2) were included in two different single-center open-label uncontrolled clinical trials. All patients presented skin dryness according to the Scaling Roughness Redness and Cracks (SRRC) scale, and pruritus and/or insomnia. They applied the dermo-cosmetic product Medi-Secure Atoderm Xereane (NAOS, Laboratoire Bioderma) once or twice a day. The clinical efficacy (SRRC, pruritus, and insomnia), the skin-related quality of life (Dermatological Life Quality Index, DLQI), and the subjective efficacy were assessed at the inclusion visit and after 28 days of product application, as well as the safety.
UNASSIGNED: After 28 days of application, the product significantly reduced the SRRC global score of 83% (0.9±0.8 vs 5.1±1.2) and 66% (1.4±1.2 vs 4.2±0.5), pruritus intensity of 76% (1.1±1.3 vs 4.6±2.1) and 78% (0.9±1.7 vs 4.2±2.6), and insomnia intensity of 61% (0.9±1.3 vs 2.4±2.3) and 82% (0.9±1.7 vs 4.8±2.7) in dialysis and diabetic patients, respectively. Furthermore, the product\'s application led to an improvement of the skin-related quality of life of 50% (5.4 vs 2.7; p<0.0001) in dialysis patients and 71% (6.6 vs 1.9; p<0.0001) in diabetic patients at D28. In addition, the product was greatly appreciated by all patients for its soothing, comforting, repairing, nourishing, and hydrating effects and was very well tolerated by the entire panels.
UNASSIGNED: This specific dermo-cosmetic product significantly reduces skin dryness, pruritus, and insomnia in dialysis and diabetic patients, thereby greatly improves their skin-related quality of life. By managing and avoiding bothersome symptoms associated with their disease or treatment, this ecobiological dermo-cosmetic can prevent serious complications that constitute a substantial burden on their daily life.